commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
Published 1 year ago • 519 plays • Length 5:30Download video MP4
Download video MP3
Similar videos
-
1:47
the commands study: luspatercept versus epoetin alfa for esa-naïve lower-risk mds-associated anemia
-
4:36
commands: luspatercept versus epoetin alfa in lr-mds-associated anemia - results & caveats
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:06
commands trial: luspatercept vs epoetin alfa in lower-risk mds
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
1:06
update on the commands trial: luspatercept is superior to esa-based therapy in lr-mds
-
0:56
luspatercept for mds-associated anemia
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
2:20
20160827 091427
-
25:30
hemolyzer 3 pro
-
3:40
no sound reblozyl® (luspatercept-aamt) for anaemia
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
1:34
follow-up from the commands trial beyond the primary endpoint: luspatercept versus esa-based therapy
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
4:19
commands study: efficacy & safety results and biomarker analysis
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
7:05
state-of-the-art treatment regimens for lr-mds